BioMarin Pharmaceutical (BMRN)
Your Dashboard
Displaying BMRN Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 96.36M
- Accounts Receivable 105.83M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.3481
- Beneish M-Score Pro
- Beta Pro
- Book Value 771.95M
- Book Value per Share 6.677
- Capital Expenditures 6.179M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing 13.45M
- Cash Financing TTM 39.21M
- Cash Investing 30.04M
- Cash Investing TTM -62.49M
- Cash Operations -7.171M
- Cash Operations TTM 15.08M
- Cash and Equivalents 82.59M
- Cash and ST Investments 232.98M
- Current Ratio 4.285
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.4512
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.21
- Earnings Per Share Growth
- Earnings Per Share TTM -0.65
- Earnings Yield -1.68%
- Effective Tax Rate TTM Pro
- Enterprise Value 4.733B
- Expenses 140.62M
- Expenses TTM 521.99M
- Free Cash Flow -13.35M
- Free Cash Flow TTM -58.08M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 85.34%
- Gross Profit TTM 368.22M
- Income from Cont. Ops Pro
- Interest Expense 1.947M
- Interest Income 0.505M
- Inventories 124.06M
- KZ Index Pro
- Liabilities 525.14M
- Long Term Debt 348.33M
- Market Cap 4.468B
- Net Income -23.97M
- Net Income TTM -73.44M
- Net PP&E 264.32M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 38.64
- Price / Book Value 5.787
- Price / Sales Ratio 9.96
- Price / Tangible Book Value Pro
- Profit Margin -20.55%
- R&D Expense 73.83M
- Receivables Turnover 4.227
- Retained Earnings -449.07M
- Retained Earnings Growth
- Return on Assets -5.70%
- Return on Equity -9.73%
- Return on Invested Capital Pro
- Revenue Growth 6.57%
- Revenue Per Share TTM 3.880
- Revenues 116.65M
- Revenues TTM 448.55M
- SG&A Expense 45.25M
- Shareholders Equity 771.95M
- Shares Outstanding 115.62M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 1.297B
- Total Return Price 38.64
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these BMRN related companies
BMRN News
RT @TheEquitiesRoom: Stocks trading down to 20d support: $EIX $DRI $SWI $BMC $OPTR $BMRN $HSY < nice list
about 7 days ago by 1nvestor
about 7 days ago by 1nvestor
Five Stocks Hit 52-Week Highs $RDWR $CHDN $LL $BMRN $MTH http://stks.co/3rG6 My story via @TheStreet
about 12 days ago by azendrian
about 12 days ago by azendrian
$BMRN Insider Sale: $1.5M of stock sold by Bienaime Jean Jacques between May 11, 2012 - May 14, 2012 http://stks.co/3qP6
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
$BMRN Insider Sale: $1.6M of stock sold by Davis George Eric on May 11, 2012 http://stks.co/3qOj
about 12 days ago by MarketBrief
about 12 days ago by MarketBrief
Listen to $BMRN inc. at deutsche bank ag health care conference - live at 08:00 AM, ondemand after - http://stks.co/3jp6
about 19 days ago by earningscast
about 19 days ago by earningscast
BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer
May 08, 4:05PM Benzinga
May 08, 4:05PM Benzinga
$BMRN Insider Sale: $1.1M of stock sold by Bienaime Jean Jacques between May 1, 2012 - May 2, 2012 http://stks.co/3elV
about 25 days ago by MarketBrief
about 25 days ago by MarketBrief
BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Apr 27, 3:10AM Seeking Alpha
Apr 27, 3:10AM Seeking Alpha
Listen to $BMRN Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3XW8
about 31 days ago by earningscast
about 31 days ago by earningscast
BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
Apr 26, 4:50PM Street Insider
Apr 26, 4:50PM Street Insider
$BMRN http://stks.co/3Njb $BMRN, Buy at trendline & 200 day ma support. Robust pipeline
about 41 days ago by Catalystrader
about 41 days ago by Catalystrader
UPDATE - UBS Initiates Coverage on BioMarin (BMRN) with a Buy; Accumulate on Pullback
Apr 12, 11:07AM Street Insider
Apr 12, 11:07AM Street Insider
$BMRN http://stks.co/3IgM Weekly triangle break down. Worth watch for new setup after new up correction http://stks.co/3IgN
about 47 days ago by xpertstocktrader
about 47 days ago by xpertstocktrader
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3DE1
about 54 days ago by MarketBrief
about 54 days ago by MarketBrief
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3C5Q
about 55 days ago by MarketBrief
about 55 days ago by MarketBrief
$BMRN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3Amr
about 56 days ago by MarketBrief
about 56 days ago by MarketBrief
BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA
Mar 08, 9:02AM Benzinga
Mar 08, 9:02AM Benzinga
BioMarin (BMRN) Announces Completion of Enrollment for Phase 3 Study on GALNS
Mar 08, 9:02AM Street Insider
Mar 08, 9:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMR | 18.25 | -0.17 | -0.92% | 2.815B |
| BMO | 52.99 | -0.73 | -1.36% | 33.94B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BLC | 5.85 | -0.03 | -0.51% | 608.52M |
| BKYF | 23.80 | -0.23 | -0.96% | 177.31M |
| BKT | 7.52 | +0.00 | +0.00% | |
| BKSC | 11.64 | +0.19 | +1.66% | 51.80M |
| BKS | 17.23 | +0.19 | +1.11% | 1.037B |
| BKR | 22.63 | +0.01 | +0.04% | 215.89M |
